Literature DB >> 16916124

Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.

Zahit Bolaman1, Gurhan Kadikoylu, Nihat Ozgel, Cigdem Yenisey.   

Abstract

BACKGROUND: The mechanism of the antithrombotic action of statins is unclear. We evaluated the effects of atorvastatin on the coagulation parameters and homocysteine levels of patients with primary hypercholesterolemia.
MATERIALS AND METHODS: Forty-four patients with primary hypercholesterolemia were treated with atorvastatin 10 mg/d for 24 weeks at Adnan Menderes University Medical Faculty, Division of Hematology, Aydin, Turkey. We evaluated the effects of atorvastatin on homocysteine; lipid parameters such as total cholesterol, low-density-lipoprotein (LDL) cholesterol, very-low-density-lipoprotein (VLDL) cholesterol, triglycerides, high-density-lipoprotein (HDL) cholesterol, lipoprotein (a), apolipoprotein Al and apolipoprotein B; and coagulation parameters such as fibrinogen, antithrombin-III, protein C, protein S, von Willebrand factor, D-dimer, partial thromboplastin time and prothrombin time; and hematological parameters such as hemoglobin, white blood cell and platelet counts, vitamin B12 and folic acid.
RESULTS: Atorvastatin significantly decreased the levels of total cholesterol, LDL cholesterol (p < 0.001), VLDL cholesterol, triglycerides and apo B (p < 0.001). The level of HDL cholesterol significantly increased with atorvastatin treatment (p < 0.001). Atorvastatin significantly increased the levels of fibrinogen (p < 0.001), but it had no effect on other coagulation factors and homocysteine (p > 0.05). After treatment, while vitamin B12 levels significantly increased (p < 0.05), other hematological parameters were not changed with atorvastatin (p > 0.05).
CONCLUSION: Although there were beneficial effects of atorvastatin on lipid parameters, atorvastatin did not significantly change the level of homocysteine and hematological, and coagulation parameters, with the exception of fibrinogen and vitamin B12 levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916124      PMCID: PMC2569568     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  37 in total

1.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update.

Authors:  G Maresca; A Di Blasio; R Marchioli; G Di Minno
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-06       Impact factor: 8.311

2.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.

Authors:  J R Crouse; J Frohlich; L Ose; M Mercuri; J A Tobert
Journal:  Am J Cardiol       Date:  1999-05-15       Impact factor: 2.778

3.  Plasma homocysteine levels and mortality in patients with coronary artery disease.

Authors:  O Nygård; J E Nordrehaug; H Refsum; P M Ueland; M Farstad; S E Vollset
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

4.  Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.

Authors:  P Alaupovic; T Heinonen; L Shurzinske; D M Black
Journal:  Atherosclerosis       Date:  1997-08       Impact factor: 5.162

5.  Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.

Authors:  A D Marais; J C Firth; M E Bateman; P Byrnes; C Martens; J Mountney
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-08       Impact factor: 8.311

Review 6.  Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.

Authors:  J W Eikelboom; E Lonn; J Genest; G Hankey; S Yusuf
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

7.  Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.

Authors:  Fumihiko Kushiya; Hideo Wada; Kinue Ooi; Yuko Sakurai; Akane Sakaguchi; Maki Noda; Yasunori Abe; Takahiro Nakasaki; Tetsuya Tsukada; Hiroshi Shiku; Tsutomu Nobori
Journal:  Am J Hematol       Date:  2005-01       Impact factor: 10.047

8.  Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.

Authors:  D Tousoulis; C Antoniades; E Bosinakou; M Kotsopoulou; C Tsioufis; C Tentolouris; A Trikas; C Pitsavos; C Stefanadis
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

9.  Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.

Authors:  S Colli; S Eligini; M Lalli; M Camera; R Paoletti; E Tremoli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-02       Impact factor: 8.311

10.  Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.

Authors:  Haralampos J Milionis; John Papakostas; Anna Kakafika; George Chasiotis; Konstantine Seferiadis; Moses S Elisaf
Journal:  J Clin Pharmacol       Date:  2003-08       Impact factor: 3.126

View more
  5 in total

1.  Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.

Authors:  Peer Wf Karmaus; Min Shi; Shira Perl; Angélique Biancotto; Julián Candia; Foo Cheung; Yuri Kotliarov; Neal Young; Michael B Fessler
Journal:  JCI Insight       Date:  2019-11-01

2.  Clinical effects of antiplatelet drugs and statins on D-dimer levels.

Authors:  Suzanne Schol-Gelok; Tom van der Hulle; Joseph S Biedermann; Teun van Gelder; Frederikus A Klok; Liselotte M van der Pol; Jorie Versmissen; Menno V Huisman; Marieke J H A Kruip
Journal:  Eur J Clin Invest       Date:  2018-05-13       Impact factor: 4.686

3.  Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.

Authors:  N B Adams; P L Lutsey; A R Folsom; D H Herrington; C T Sibley; N A Zakai; S Ades; G L Burke; M Cushman
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

4.  Effect of statins on platelet function in patients with hyperlipidemia.

Authors:  Joanna Sikora; Barbara Kostka; Iwona Marczyk; Urszula Krajewska; Maciej Chałubiński; Marlena Broncel
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

5.  The association between atorvastatin administration and plasma total homocysteine levels in renal transplant recipients.

Authors:  Ali Monfared; Seyyede Zeinab Azimi; Ehsan Kazemnezhad
Journal:  J Nephropathol       Date:  2016-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.